HOME >> BIOLOGY >> NEWS
Vaccine technique shows potential against common form of lung cancer

BOSTON In a demonstration of vaccine therapys potential for treating lung cancer, Dana-Farber Cancer Institute scientists and their associates report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). Moreover, the vaccine was found to be non-toxic and well-tolerated.

Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases. (Phase I trials are designed primarily to assess the safety of an experimental treatment.)

"This work represents a new approach to a vaccine for lung cancer patients, says senior author Glenn Dranoff, MD, of Dana-Farber. "Were still at an early stage, but the results of this study are encouraging. They offer a 'proof of principle' that this technique can strengthen the normal immune response to NSCLC tumors and will help form the basis for testing the vaccine in patients with earlier stage lung cancer."

The technique was originally developed for patients with advanced melanoma, a form of cancer that begins in the skin but can be deadly if allowed to spread to other parts of the body.

The researchers created the melanoma vaccine by removing a portion of a patients tumor and using specially equipped viruses to insert a gene known as GM-CSF into the tumor cells. After being radiated and injected into the patient, the manipulated tumor cells began producing the granulocyte-macrophage colony-stimulating factor (GM-CSF) protein, which acted as a magnet for an immune system attack on tumor cells. As the researchers had hoped, the vaccine elicited a potent, long-lasting immune response targeted at the melanoma tumor cells and produced only minor side effects.

In the lung cancer study,
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
13-Feb-2003


Page: 1 2

Related biology news :

1. Hope Clinic of Emory Vaccine Center receives CDC contract
2. Vaccines against foodborne disease on horizon
3. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
4. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
5. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
6. Vaccine prevents stroke in rats
7. Vaccine puts blood-sucking ticks off their food
8. Vaccine protects against fatal West Nile complication
9. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
10. Vaccine controls AIDS in monkeys, researchers report in Science
11. Vaccine put into tomatoes shows promise fighting virus in lab tests

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine technique shows potential against common form lung cancer

(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
(Date:4/16/2015)... San Francisco, CA (PRWEB) April 16, 2015 ... is scheduled to report first quarter results on Thursday, ... the announcement, Cytokinetics’ senior management will host a conference ... and financial results and the company’s outlook for the ... and can be accessed from the homepage and in ...
(Date:4/16/2015)... Regis Technologies looks forward to being ... Research (AACR) annual meeting. Regis will exhibit at this ... April 18, in Philadelphia and running through April 22, ... the oldest and largest organization focused on cancer research. ... partners with survivors to promote awareness and research funding. ...
(Date:4/16/2015)... Mass. , April 16, 2015  In recognition of ... collaborated with hemophilia advocacy groups to illuminate more than 15 ... , including Boston,s Zakim Bridge and ... New Orleans, Mercedes-Benz Superdome and ... occur during the evening of April 17, and coincide with ...
(Date:4/16/2015)... 2015 ChemRar High ... and R&D group, and Lancet, Russian Distribution ... and commercialization of new medicines in ... to stimulate the innovative development of the ... http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2
Cached News: